Pear Therapeutics, Inc., recently announced the availability of Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia.
Pear Therapeutics, Inc., recently announced the availability of Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia.
© 2024 Arboretum Ventures. Privacy Policy | Cookie Policy | Terms Policy